Top Back to top

Survey on the use of SGLT2 inhibitors in cell therapy including autologous and allogeneic hematopoietic stem cell transplantation and CART cell therapy

Transplant Complications Working Party (TCWP)
Study type:
Study number:
 
Type of Stem Cell Treatment:
Allogeneic
Autologous
CAR T
Diseases:
All diseases
Short title:
SGLT2i Survey
Primary objective:
 
Key inclusion criteria:
 
Country:
All EBMT member countries
Principal investigator:
Christian Schultze-Florey
EBMT Study coordinator:
William Boreland
Study coordinator email:
william.boreland@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Not applicable to surveys
Categories of personal data collected:
Not applicable to surveys
Centers’ contact / Centers’ policies
Recipients who may access the data:
Not applicable to surveys
Paris Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
Not applicable to surveys

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
Not applicable to surveys
Retention Schedule (if possible):
Not applicable to surveys